<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04612452</url>
  </required_header>
  <id_info>
    <org_study_id>DTG-SWITCH Study protocol</org_study_id>
    <nct_id>NCT04612452</nct_id>
  </id_info>
  <brief_title>The DTG-SWITCH Study: Longitudinal Analysis of Virologic Failure and Drug Resistance at and After Switching to Dolutegravir-based First-line ART</brief_title>
  <acronym>DTG-SWITCH</acronym>
  <official_title>The DTG-SWITCH Study: Longitudinal Analysis of Virologic Failure and Drug Resistance at and After Switching to Dolutegravir-based First-line ART</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Bern</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of KwaZulu</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Lighthouse Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centre for Infectious Disease Research in Zambia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Bern</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective observational cohort study of 2820 patients on first-line ART switching&#xD;
      to a DTG-based first-line regimen, according to the standard of care. The study is conducted&#xD;
      in Malawi and Zambia, in ART programs that participate in the IeDEA collaboration. Sequencing&#xD;
      will be done on blood samples of patients with a viral load above 400 copies/mL to identify&#xD;
      mutations.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Dolutegravir (DTG), a second-generation integrase strand transfer inhibitor (InSTI), is&#xD;
      widely used in high-income countries and is recommended by the World Health Organization&#xD;
      (WHO) as an alternative first-line ART regimen. In countries where viral load monitoring is&#xD;
      not routinely available many patients on first-line ART will be switched to a DTG-based&#xD;
      regimen despite the detectable viral load, which could increase the risk of selection of&#xD;
      resistance to DTG as the majority of patients with virologic failure on first-line EFV-based&#xD;
      ART have NRTI mutations. The investigators hypothesize that the proportion of patients&#xD;
      experiencing virologic failure 48 and 96 weeks after switching to a DTG-based regimen will be&#xD;
      higher in patients who switched with virologic failure (VL&gt;400 copies/mL) compared to&#xD;
      patients who switched with suppressed viral replication (VL&lt;400 copies/mL). This is a&#xD;
      prospective observational cohort study of 2820 patients on first-line ART switching to a&#xD;
      DTG-based first-line regimen, according to the standard of care. The study is conducted in&#xD;
      Malawi and Zambia, in ART programs that participate in the IeDEA collaboration. At the time&#xD;
      of switching to DTG, a baseline study assessment will be done, and a blood sample will be&#xD;
      taken. Sequencing will be done on blood samples of patients with a viral load above 400&#xD;
      copies/mL to identify mutations.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 5, 2019</start_date>
  <completion_date type="Anticipated">November 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>To compare the proportion of patients with VF at 48 weeks between patients with and without VF at baseline.</measure>
    <time_frame>48 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To compare the proportion of patients with VF at 96 weeks between patients with and without VF at baseline.</measure>
    <time_frame>96 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To compare the incidence of TLD drug resistances at 48 and 96 weeks between patients with and without VF at switch.</measure>
    <time_frame>48 and 96 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To estimate the proportion of HIV-infected patients with VF at baseline.</measure>
    <time_frame>Baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To compare the proportion of patients with VF at 48 weeks and 96 weeks in patients with VF at baseline who have at least one versus no fully active NRTI on resistance testing.</measure>
    <time_frame>48 and 96 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prevalence of neuropsychiatric symptoms at baseline, 48 weeks and 96 weeks.</measure>
    <time_frame>48 and 96 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prevalence of insomnia at baseline, 48 weeks and 96 weeks.</measure>
    <time_frame>48 and 96 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess weight gain from baseline to 48 and 96 weeks.</measure>
    <time_frame>48 and 96 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To monitor levels of adherence at baseline and after 48 and 96 weeks.</measure>
    <time_frame>48 and 96 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess retention on DTG-based regimens care at 48 and 96 weeks.</measure>
    <time_frame>48 and 96 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess overall retention in care at baseline, 48 and 96 weeks.</measure>
    <time_frame>48 and 96 weeks</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">2820</enrollment>
  <condition>Hiv</condition>
  <condition>Drug Resistancy</condition>
  <condition>Virologic Failure</condition>
  <arm_group>
    <arm_group_label>Lighthouse Trust in Lilongwe</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>CIDRZ in Lusaka</arm_group_label>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        People living with HIV.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Patients&#xD;
&#xD;
          -  On first-line ART for 6 months or longer&#xD;
&#xD;
          -  Switching to any DTG-based treatment&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  No informed consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Matthias Egger</last_name>
    <role>Study Director</role>
    <affiliation>University of Berne</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Stefanie Hossmann, MSc</last_name>
    <phone>+41316313087</phone>
    <email>stefanie.hossmann@ctu.unibe.ch</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Per Von Groote, PhD</last_name>
    <phone>+41 31 631 30 76</phone>
    <email>per.vongroote@ispm.unibe.ch</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Lighthouse Trust</name>
      <address>
        <city>Lilongwe</city>
        <country>Malawi</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>CIDRZ</name>
      <address>
        <city>Lusaka</city>
        <country>Zambia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guy K Muula, PhD</last_name>
      <email>Guy.Muula@cidrz.org</email>
    </contact>
  </location>
  <location_countries>
    <country>Malawi</country>
    <country>Zambia</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>October 27, 2020</study_first_submitted>
  <study_first_submitted_qc>October 27, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 3, 2020</study_first_posted>
  <last_update_submitted>October 27, 2020</last_update_submitted>
  <last_update_submitted_qc>October 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 3, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hiv, drug resistancy, virologic failure, DTG-based regimen</keyword>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

